Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations (Q38623310)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 July 2017

Language	Label	Description	Also known as
English	Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations	scientific article published on 26 July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations (English)

1 reference

Europe PubMed Central

4 September 2017

Gram-negative bacteria

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Luis Martínez Martínez

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Benito Almirante

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jordi Carratala

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Valentín Cuervas-Mons

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Pilar Martín-Dávila

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Elena Pérez-Nadales

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

J M Aguado

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J T Silva

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M Fernández-Ruiz

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Fortún

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

C Gudiol

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

E Vidal

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

L Almenar

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

R Cantón

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J J Caston

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

E Cercenado

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J M Cisneros

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M G Crespo-Leiro

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Elizalde-Fernández

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M C Fariñas

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Gavaldà

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M J Goyanes

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

B Gutiérrez-Gutiérrez

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

D Hernández

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

R López-Andujar

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

F López-Medrano

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M Montejo

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Moreno

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Oliver

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Román-Broto

34

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

R San-Juan

35

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

D Serón

36

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Solé-Jover

37

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M Valerio

38

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

P Muñoz

39

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Torre-Cisneros

40

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Spanish Society of Transplantation (SET)

41

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC)

42

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016)

43

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

26 July 2017

1 reference

Europe PubMed Central

4 September 2017

Transplantation Reviews

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

36-57

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

The global threat of antimicrobial resistance: science for intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Losing ground: multidrug-resistant bacteria in solid-organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant bacteria in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant gram-negative bacteria infections in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Therapeutic options for vancomycin-resistant enterococcal bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Updated functional classification of beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Extended-spectrum beta-lactamases: a clinical update

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

AmpC beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Klebsiella necrotizing soft tissue infections in liver transplant recipients: a case series.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Bloodstream Infections Among Transplant Recipients: Results of a Nationwide Surveillance in Spain

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Incisional surgical infection in heart transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Acinetobacter mediastinitis in a heart transplant patient.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Aspergillus infections in lung transplant recipients: risk factors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant Acinetobacter baumannii infections in lung transplant patients in the cardiothoracic intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Impact ofBurkholderiaInfection on Lung Transplantation in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Bacteremia in lung transplant recipients in the current era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant Klebsiella pneumoniae acquisition in lung transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pseudomonas Aeruginosa Infection Among Liver Transplant Recipients: A Clinical Analysis of 15 Cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum β-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Urinary tract infections in special populations: diabetes, renal transplant, HIV infection, and spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Urinary tract infections in the early posttransplant period after simultaneous pancreas-kidney transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Detección fenotípica de mecanismos de resistencia en microorganismos gramnegativos

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Detection and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae in high-risk patients in an Irish tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-Resistant Bacterial Donor-Derived Infections in Solid Organ Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Favorable outcome in a renal transplant recipient with donor-derived infection due to multidrug-resistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

High prevalence of extended-spectrum beta-lactamase-producing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Antibiotic prophylaxis for cardiac surgery in a setting with high prevalence of extended-spectrum beta-lactamase-producing Gram-negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Prevalence and risk factors for carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among patients prior to bowel surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Environmental contamination with extended-spectrum β-lactamases: is there any difference between Escherichia coli and Klebsiella spp?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Multidrug-resistant bacterial infection in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Strategies to prevent healthcare-associated infections through hand hygiene

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Controversies in guidelines for the control of multidrug-resistant Gram-negative bacteria in EU countries.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Managing transmission of carbapenem-resistant enterobacteriaceae in healthcare settings: a view from the trenches

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Infection acquisition following intensive care unit room privatization

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Control of infections due to extended-spectrum beta-lactamase-producing organisms in hospitals and the community

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Decontamination of the digestive tract and oropharynx in ICU patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Survival benefit of the full selective digestive decontamination regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Nebulised colistin for ventilator-associated pneumonia prevention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem-Resistant Enterobacteriaceae Acquired Before Liver Transplantation: Impact on Recipient Outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for KPC-producing Klebsiella pneumoniae bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Increasing incidence of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Belgian hospitals

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Do CTX-M beta-lactamases hydrolyse ertapenem?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Correlation between penicillin-binding protein 2 mutations and carbapenem resistance in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The Problem of Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae Detection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact of resistance on outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Incisional surgical site infection in kidney transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Hand Hygiene, Cohorting, or Antibiotic Restriction to Control Outbreaks of Multidrug-Resistant Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The management of multidrug-resistant Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE).

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-dir

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for pneumonia caused by multidrug-resistant Gram-negative bacilli among liver recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology and risk factors of multidrug-resistant bacteria in respiratory samples after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The increasing threat of Pseudomonas aeruginosa high-risk clones.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The problems of antibiotic resistance in cystic fibrosis and solutions

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Fatal hemorrhage in two renal graft recipients with multi-drug resistant Pseudomonas aeruginosa infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The deceased organ donor with an "open abdomen": proceed with caution

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Outcomes of lung transplantation for cystic fibrosis in a large UK cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hands of a health care worker

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Contribution of tap water to patient colonisation with Pseudomonas aeruginosa in a medical intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Transfer of multidrug-resistant bacteria to healthcare workers' gloves and gowns after patient contact increases with environmental contamination

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Bacterial contamination of the hands of doctors: a study in the medicine and dermatology wards

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Epidemiology of multi-drug-resistant gram-negative bacteria: data from an university hospital over a 36-month period

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Diagnostic accuracy of surveillance cultures to detect gastrointestinal colonization with multidrug-resistant gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Renal toxicity due to inhaled tobramycin in lung transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

High mortality associated with Acinetobacter species infection in liver transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Liver transplantation in patients infected with gram-negative bacteria: non-Acinetobacter baumannii and Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem-resistant Acinetobacter baumannii acquired before liver transplantation: Impact on recipient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical significance of surveillance culture in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: an analysis of the epidemiology, risk factors, and outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Risk factors for Enterobacteriaceae bacteremia after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Molecular Epidemiology and Mechanisms of Carbapenem Resistance of Acinetobacter spp. in Asia and Oceania

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin, mechanisms and prevalence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin heteroresistance in acinetobacter and its association with previous colistin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of Acinetobacter species from a Korean university hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Acinetobacter baumannii infection in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

The Distribution, Drug Resistance, and Clinical Characteristics of Acinetobacter baumannii Infections in Solid Organ Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical practice guidelines for antimicrobial prophylaxis in surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Environmental exposure to carbapenem-resistant Acinetobacter baumannii as a risk factor for patient acquisition of A. baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Impact of an Infection Control and Antimicrobial Stewardship Program on Solid Organ Transplantation and Hepatobiliary Surgical Site Infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Inhaled Antibiotics for Gram-Negative Respiratory Infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Rapid development of Acinetobacter baumannii resistance to tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.07.001

7 January 2021

Identifiers

10.1016/J.TRRE.2017.07.001

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811074%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38623310&oldid=1771104742"